# Beuropean Congress on Immunotherapies in Cancer™



21-22 September 2018



Hilton Barcelona 589-591 Avenida Diagonal Barcelona, Spain 08014

# Complimentary Offer! Register today for FREE with code ELC18SOC



### **MEET THE PROGRAM CO-CHAIRS:**



ANTONI RIBAS, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular and Medical
Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program
Jonson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA



CAROLINE ROBERT, MD, PhD
Head of the Dermatology Unit
Department of Medicine
Gustave Roussy and Paris-Sud University
Villeiuif Grand -Paris. France

### **OVERVIEW**

The European Congress on Immunotherapies in Cancer™ is a 2-day comprehensive and interactive program focused exclusively on immunotherapies and their practical application to the management of cancer. This intensive, interactive program will provide you with a comprehensive review of key data sets that are most relevant for managing some of the most difficult-to-treat forms of cancer. The program will focus on scientific advances, recent clinical trial results that shape current and evolving uses of these approaches, proactive methods to monitor and mitigate treatment-related adverse events, current and emerging testing methods, and multidisciplinary team approaches to optimize the use of immunotherapeutic Co-Organizer strategies to treat cancer.

PER® complies with all applicable laws, rules, and regulations and as such, we may be required to collect information on transfer of value provided to healthcare professionals or health care organization.



gética

For more information, visit us online now at... gotoper.com/europe/go/ECIC18

## **AGENDA**

# FRIDAY, 21 SEPTEMBER 2018

- FRIDA	AT, ZI SEPIEWIBER ZUIB	100000000000000000000000000000000000000
The Sci	ience of Cancer Immunotherapy	Moderators: Antoni Ribas, MD, PhD and Caroline Robert, MD, PhD
9:50	Welcome and Presession Survey	Antoni Ribas, MD, PhD and Caroline Robert, MD, PhD
10:00	Opening Keynote: NK Cells in Cancer Immunotherapy	Lewis L. Lanier, PhD
10:30	Tumor-Infiltrating Lymphocytes	Inge Marie Svane, MD, PhD
11:00	Translational Control and Immunotherapy	Stephan Vagner, PhD
11:30	Morning Break	
The Sci	ience of Cancer Immunotherapy (cont.)	Moderator: José Antonio Lopez-Martin, MD, PhD
11:50	TBA	Sebastian Amigorena, PhD
12:20	Where Are We With Immunotherapy for GI Cancers?	TBD
12:50	The Interplay Between Immune Response and Therapy in Breast Cancer	Fabrice Andre, MD, PhD
13:20	Panel Discussion "How Can We Efficiently Develop IO Agents for Solid Cancers?" Postsession Survey	Chair: José Antonio Lopez-Martin, MD, PhD Discussants: Sebastian Amigorena, PhD; Fabrice Andre, MD, PhD; Lewis L. Lanier, PhD; Josep Tabernero, MD, PhD; Stephan Vagner, PhD
13:50	Lunch Break	
Immun	o-Oncology in the Clinic - I	Moderator: José Antonio Lopez-Martin, MD, PhD
14:50	Presession Survey	José Antonio Lopez-Martin, MD, PhD
14:55	Immunotherapeutic Strategies for Cancers of the Lung, Head, and Neck	Roman Perez-Soler, MD
15:55	Challenging Case Debate Postsession Survey	Discussants: José Antonio Lopez-Martin, MD, PhD and Roman Perez-Soler, MD
16:25	Afternoon Break	
Immuno-Oncology in the Clinic - I (cont.)  Moderator: Joan Carles, MD, PhD		
Immun	o-Oncology in the Clinic - I (cont.)	Moderator: Joan Carles, MD, PhD
16:45	o-Oncology in the Clinic - I (cont.)  Emerging Standards of Care in Renal Cell Carcinoma	Moderator: Joan Carles, MD, PhD  Laurence Albiges, MD, PhD
16:45	Emerging Standards of Care in Renal Cell Carcinoma	Laurence Albiges, MD, PhD
16:45 17:15	Emerging Standards of Care in Renal Cell Carcinoma  Optimizing Outcomes With Immunotherapy for Bladder Cancer  Panel Discussion: How Should We Apply the Anti-PD-1/L1  Data and Combinations to Our Practices?	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD;
16:45 17:15 17:45	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD;
16:45 17:15 17:45 18:15 17:50	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD;
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall)	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immun	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immune 9:50	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II Welcome and Presession Survey	Laurence Albiges, MD, PhD  Joaquim Bellmunt, MD, PhD  Chair: Joan Carles, MD, PhD  Discussants: Joaquim Bellmunt, MD, PhD;  Bernard Escudier, MD  Moderator: John Haanen, MD, PhD  John Haanen, MD, PhD
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immun 9:50 9:55	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II Welcome and Presession Survey Immunotherapy for Melanoma	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD John Haanen, MD, PhD Caroline Robert, MD PhD
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immun 9:50 9:55 10:25	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II  Welcome and Presession Survey Immunotherapy for Melanoma Mechanistic Basis of Immune Responses to Melanoma	Laurence Albiges, MD, PhD  Joaquim Bellmunt, MD, PhD  Chair: Joan Carles, MD, PhD  Discussants: Joaquim Bellmunt, MD, PhD;  Bernard Escudier, MD  Moderator: John Haanen, MD, PhD  John Haanen, MD, PhD  Caroline Robert, MD PhD  John Haanen, MD, PhD
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immun 9:50 9:55	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II Welcome and Presession Survey Immunotherapy for Melanoma	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD John Haanen, MD, PhD Caroline Robert, MD PhD
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immun 9:50 9:55 10:25	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II  Welcome and Presession Survey Immunotherapy for Melanoma Mechanistic Basis of Immune Responses to Melanoma Medical Crossfire®: Adjuvant Therapy for Melanoma:	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD John Haanen, MD, PhD Caroline Robert, MD PhD John Haanen, MD, PhD Chair: John Haanen, MD, PhD Pro Immunotherapy: Caroline Robert, MD, PhD
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immun 9:50 9:55 10:25 10:55	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall)  o-Oncology in the Clinic - II  Welcome and Presession Survey Immunotherapy for Melanoma  Mechanistic Basis of Immune Responses to Melanoma  Medical Crossfire®: Adjuvant Therapy for Melanoma: Immunotherapy Versus BRAF-Targeted Therapy	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD John Haanen, MD, PhD Caroline Robert, MD PhD John Haanen, MD, PhD Chair: John Haanen, MD, PhD Pro Immunotherapy: Caroline Robert, MD, PhD
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immun 9:50 9:55 10:25 10:55	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II Welcome and Presession Survey Immunotherapy for Melanoma Mechanistic Basis of Immune Responses to Melanoma Medical Crossfire®: Adjuvant Therapy for Melanoma: Immunotherapy Versus BRAF-Targeted Therapy  Morning Break	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD John Haanen, MD, PhD Caroline Robert, MD PhD John Haanen, MD, PhD Chair: John Haanen, MD, PhD Pro Immunotherapy: Caroline Robert, MD, PhD Pro BRAF Therapy: Antoni Ribas, MD, PhD Moderators: Antoni Ribas, MD, PhD and Caroline
16:45 17:15 17:45 18:15 17:50 <b>SATU</b> 8:00 Immun 9:50 9:55 10:25 10:55	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II  Welcome and Presession Survey Immunotherapy for Melanoma Mechanistic Basis of Immune Responses to Melanoma Medical Crossfire®: Adjuvant Therapy for Melanoma: Immunotherapy Versus BRAF-Targeted Therapy  Morning Break Points and CARs	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD John Haanen, MD, PhD Caroline Robert, MD PhD John Haanen, MD, PhD Chair: John Haanen, MD, PhD Pro Immunotherapy: Caroline Robert, MD, PhD Pro BRAF Therapy: Antoni Ribas, MD, PhD Moderators: Antoni Ribas, MD, PhD and Caroline Robert, MD, PhD
16:45 17:15 17:45 18:15 17:50 SATUI 8:00 Immun 9:50 9:55 10:25 10:55 Checkp	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II  Welcome and Presession Survey Immunotherapy for Melanoma Mechanistic Basis of Immune Responses to Melanoma Medical Crossfire®: Adjuvant Therapy for Melanoma: Immunotherapy Versus BRAF-Targeted Therapy  Morning Break CAR-T Therapy for Leukemia and Lymphoma	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD John Haanen, MD, PhD Caroline Robert, MD PhD John Haanen, MD, PhD Chair: John Haanen, MD, PhD Pro Immunotherapy: Caroline Robert, MD, PhD Pro BRAF Therapy: Antoni Ribas, MD, PhD Moderators: Antoni Ribas, MD, PhD and Caroline Robert, MD, PhD
16:45 17:15 17:45  18:15 17:50 SATUI  8:00 Immun  9:50 9:55 10:25 10:55  Checkp  11:50 12:20	Emerging Standards of Care in Renal Cell Carcinoma Optimizing Outcomes With Immunotherapy for Bladder Cancer Panel Discussion: How Should We Apply the Anti-PD-1/L1 Data and Combinations to Our Practices? Postsession Survey Adjourn Poster Networking Reception (Exhibit Hall)  RDAY, 22 SEPTEMBER 2018  Breakfast and Poster Viewing (Exhibit Hall) o-Oncology in the Clinic - II  Welcome and Presession Survey Immunotherapy for Melanoma Mechanistic Basis of Immune Responses to Melanoma Medical Crossfire®: Adjuvant Therapy for Melanoma: Immunotherapy Versus BRAF-Targeted Therapy  Morning Break Points and CARS  CAR-T Therapy for Leukemia and Lymphoma Postsession Survey and Discussion	Laurence Albiges, MD, PhD Joaquim Bellmunt, MD, PhD Chair: Joan Carles, MD, PhD Discussants: Joaquim Bellmunt, MD, PhD; Bernard Escudier, MD  Moderator: John Haanen, MD, PhD John Haanen, MD, PhD Caroline Robert, MD PhD John Haanen, MD, PhD Chair: John Haanen, MD, PhD Pro Immunotherapy: Caroline Robert, MD, PhD Pro BRAF Therapy: Antoni Ribas, MD, PhD Moderators: Antoni Ribas, MD, PhD and Caroline Robert, MD, PhD Manel Joan, MD  Manel Joan, MD